| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
H-Leu-ol targets aminopeptidases as a competitive inhibitor with a Ki of 17 μM. As a leucine-derived amino alcohol, it also serves as a chiral building block for the synthesis of enantiomerically pure compounds. Its primary applications are in organic synthesis and as a research tool for studying aminopeptidase function.
|
|---|---|
| ln Vitro |
In vitro, H-Leu-ol acts as a competitive aminopeptidase inhibitor with a Ki of 17 μM. Amino acid derivatives have been commercially used as ergogenic supplements, influencing anabolic hormone secretion, fuel availability, mental performance, and prevention of muscular damage. H-Leu-ol's utility extends to chiral synthesis and pharmaceutical research.
|
| ln Vivo |
In vivo activity data for H-Leu-ol as a standalone compound is not extensively reported. As an aminopeptidase inhibitor, it may affect peptide metabolism and protein turnover in vivo. Compounds synthesized using this chiral building block may be evaluated in animal models for therapeutic applications.
|
| Enzyme Assay |
In vitro enzyme inhibition assays for H-Leu-ol involve measuring its inhibition of aminopeptidase activity. Purified aminopeptidase is incubated with the compound at various concentrations in appropriate buffer with substrate. Enzyme activity is measured by fluorometric or spectrophotometric detection of released product. Ki values are calculated from dose-response curves. IC50 and Ki = 17 μM.
|
| Cell Assay |
Cell-based protocols for H-Leu-ol are not well established as it is primarily a synthetic building block. Aminopeptidase inhibition can be studied in cell lysates or intact cells using fluorogenic substrates. Cells are treated with H-Leu-ol at various concentrations, and aminopeptidase activity is measured. Concentrations typically range from 1-100 µM for 1-24 hours.
|
| Animal Protocol |
In vivo animal study protocols for H-Leu-ol would depend on the specific application. If used as a building block for drug candidates, standard PK/PD studies would apply. The compound itself may be administered to study aminopeptidase inhibition in vivo, with blood and tissue samples collected for analysis of enzyme activity and compound levels.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for H-Leu-ol as a standalone compound is limited. The compound has a molecular weight of 117.19 g/mol, formula C6H15NO, and CAS number 7533-40-6. Melting point is 56-58°C. Boiling point is 208-210°C. Density is 0.917 g/mL. Optical rotation is 3° (589nm, c=9, ethanol). Appearance is white or almost white crystalline powder.
|
| Toxicity/Toxicokinetics |
Limited toxicological data is available for H-Leu-ol. The compound is for research use only. Standard safety precautions should be observed. No specific toxicity studies have been reported. It is not intended for human therapeutic use.
|
| References | |
| Additional Infomation |
L(+)-Leucine is an amino alcohol.
H-Leu-ol (CAS#: 7533-40-6) is also known as L-Leucinol, (S)-(+)-Leucinol, (2S)-2-amino-4-methylpentan-1-ol, and (S)-2-amino-4-methylpentan-1-ol. It is a competitive aminopeptidase inhibitor with Ki of 17 μM and a chiral building block for organic synthesis. It has no approved therapeutic indications. |
| Molecular Formula |
C6H15NO
|
|---|---|
| Molecular Weight |
117.1894
|
| Exact Mass |
117.115
|
| Elemental Analysis |
C, 61.49; H, 12.90; N, 11.95; O, 13.65
|
| CAS # |
7533-40-6
|
| Related CAS # |
D-Leucinol; 53448-09-2
|
| PubChem CID |
111307
|
| Appearance |
Colorless to light yellow Liquid
|
| Density |
0.917
|
| Boiling Point |
208-210 ºC
|
| Melting Point |
66 - 70ºC
|
| Flash Point |
90 ºC
|
| Vapour Pressure |
0.1±0.8 mmHg at 25°C
|
| Index of Refraction |
1.4496-1.4516
|
| LogP |
0.45
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
8
|
| Complexity |
54.5
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O([H])C([H])([H])[C@]([H])(C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])N([H])[H]
|
| InChi Key |
VPSSPAXIFBTOHY-LURJTMIESA-N
|
| InChi Code |
InChI=1S/C6H15NO/c1-5(2)3-6(7)4-8/h5-6,8H,3-4,7H2,1-2H3/t6-/m0/s1
|
| Chemical Name |
(2S)-2-amino-4-methylpentan-1-ol
|
| Synonyms |
Leucinol; L-Leucinol; (+)-Leucinol; L-(+)-Leucinol; AI3-62983; (S)-(+)-Leucinol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~853.32 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (21.33 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (21.33 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (21.33 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.5332 mL | 42.6658 mL | 85.3315 mL | |
| 5 mM | 1.7066 mL | 8.5332 mL | 17.0663 mL | |
| 10 mM | 0.8533 mL | 4.2666 mL | 8.5332 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
